According to a recent press release, the FDA has updated its recommendations regarding NuVasive Precice’s intramedullary lengthening system.
“The update is to ensure health care providers are aware of the current indications and the instructions for use for the [intramedullary limb lengthening] IMLL system,” members of the FDA wrote in the release. “We are reminding health care providers that the device should be removed after 1 year.”
According to the release the Precice IMLL System is intended for patients over 18 years of age for limb lengthening and open.
